14 September 2023  
EMA/CHMP/354618/2023  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Nordimet 
methotrexate 
On 14 September 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Nordimet. The marketing authorisation holder for this medicinal product is Nordic Group B.V. 
The CHMP adopted a new indication to include treatment of moderate psoriasis in adults who are 
candidates for systemic therapy. For information, the full indications for Nordimet will be as follows:2 
Nordimet is indicated for the treatment of: 
•  active rheumatoid arthritis in adult patients,  
•  polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to 
nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,  
•  moderate to severe plaque psoriasis in adults who are candidates for systemic 
therapysevere recalcitrant disabling psoriasis, which is not adequately responsive to other 
forms of therapy such as phototherapy, psoralens and ultraviolet A (PUVA), and retinoids, and 
severe psoriatic arthritis in adult patients, 
• 
induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in 
combination with corticosteroids and for maintenance of remission, as monotherapy, in 
patients who have responded to methotrexate. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR) and will be available in all official European Union languages after a decision on this change to the 
marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
